Clarity Pharmaceuticals (ASX:CU6) Change In Payables And Accrued Expense : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Change In Payables And Accrued Expense?

Clarity Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Clarity Pharmaceuticals's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Clarity Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means Clarity Pharmaceuticals's Accounts Payable & Accrued Expense stayed the same from Jun. 2022 to Jun. 2023 .

Clarity Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Clarity Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Change In Payables And Accrued Expense Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Change In Payables And Accrued Expense

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial			-	-	-	-	-

Clarity Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Clarity Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (ASX:CU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

CLRPF:USA

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines